Lisa Pham is a Reporter at Bloomberg. She covers a diverse range of topics including finance, trading, energy and mining, as well as healthcare and pharmaceuticals, often focusing on themes such as global markets and international finance. Lisa's work has been featured in prominent publications including Bloomberg Law, The Washington Post, and Fortune.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Lisa Pham's coverage primarily focuses on health and finance, with an emphasis on investment analysis and citing data. To effectively reach out to her, consider offering insights or expert commentary related to the intersection of health and finance such as the impact of healthcare trends on stock markets, emerging opportunities in the pharmaceutical industry, or analyses regarding the financial implications of health-related regulatory changes.
Given that Lisa covers ESG campaigns falling out of favor with activist investors among other topics like obesity drugs and retail, she may be interested in receiving pitches from experts who can provide unique perspectives on evolving consumer trends in these areas. If you have proprietary data or specialized knowledge about how these factors are impacting industries from a financial perspective, it could make for a compelling pitch to Lisa.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jef Feeley, Lisa Pham
Bayer AG won a legal fight that brings the company a step closer to getting Missouri state court approval for a proposed $7.25 billion settlement of thousands of U.S. cancer lawsuits alleging Roundup weedkiller caused cancer.
By: Lisa Pham, Fabienne Kinzelmann, Sonja Wind
The Russia-Ukraine war, China’s rare earth controls and the Iran turmoil risk hurting a promising corner of the $280 billion cancer-treatment market.
The rollout of a new hearing aid equipped with artificial intelligence is driving the shares of Denmark’s Demant A/S to their best quarterly performance since 2000.
By: Lisa Pham, Naomi Kresge
Abivax SA soared as much as 27% after a clinical-trial update soothed some investors’ concerns about whether cancer could be a potential side effect of the biotech’s most promising experimental drug.
By: Lisa Pham, Ashleigh Furlong
Galderma Group AG shares slumped the most in more than a year after the Swiss dermatology firm said the US Food and Drug Administration had turned down its rival Botox treatment Relfydess.
AI can make mistakes, and that’s a red line in healthcare.
Once a market standout, Ocado Group Plc shares are showing signs of life again after a bruising decline.
It’s been a big week for biotech stocks on both sides of the Atlantic.
Once one of Britain’s most celebrated biotech listings, Oxford Nanopore Technologies Plc is on the comeback trail after its early promise gave way to years of share-price underperformance.
By: Avalon Pernell, Lisa Pham
Drugmakers found a promising cure for the obesity epidemic and their stocks were rewarded for it. Now, investors are salivating over a new crop of companies tackling a more purely aesthetic problem: baldness.
